Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 1998

View Archived Issues

L-Glutamine therapy beneficial for sickle cell anemia

TR1, new member of the TNFR superfamily and target for treating metabolic bone diseases

PKA I may be a valid target for immunomodulation in the HIV-infected patient

Bromocriptine reduces prolactin levels in patients with androgen-independent prostate cancer

Potent anti-HSV-1 activity demonstrated with BILD-1633-SE in vivo

Matrix granted Japanese patent; U.S. patent reissued

Anika: Q2 1998 highlights

Diacrin: Q2 1998 highlights

Salix: Q2 1998 highlights

Results support development of beta-L-Fd4C as an expanded-spectrum anti-HBV drug

Patent issued for Techniclone's Vascular Targeting Agent technology

Carotid artery intimal thickening prevented by TAS-301

New COX-2 inhibitors in early development at American Home

P&U discloses new distamycin derivatives with antitumor/antiviral efficacy

Two new series of PDE4 inhibitors reported by Byk Gulden

Otsuka adds new antidiabetic candidates to R&D pipeline

Insulin-sensitizing guanidine compounds discovered by Yamanouchi

Nonamine compounds inhibit monoamine transporters, contrary to prevailing beliefs

SynPhar's HLE inhibitors show unique potential in preventing lung injury

Ligand-Seragen merger process now completed

First filing for Novo Nordisk's fast-acting insulin analogue

The Medicines Company acquires clinical-stage antimigraine drug for development

SB-237376, a new antiarrhythmic agent with a dual mechanism of action and enhanced safety

Kissei studies beta-adrenergic drug for use in patients with urolithiasis